tetano
Editor, Senior Moderator
Expert Rev Clin Immunol
. 2021 Dec 29.
doi: 10.1080/1744666X.2022.2017282. Online ahead of print.
Evaluating the role of chemokines and chemokine receptors involved in coronavirus infection
Gema Olivarria[SUP] 1 [/SUP], Thomas E Lane[SUP] 1 2 3 [/SUP]
Affiliations
Abstract
Introduction: Coronaviruses are a large family of positive-stranded non-segmented RNA viruses with genomes of 26-32 kilobases in length. Human coronaviruses are commonly associated with mild respiratory illness; however, the past three decades have seen the emergence of severe acute respiratory coronavirus (SARS-CoV), middle eastern respiratory coronavirus (MERS-CoV), and SARS-CoV-2 which is the etiologic agent for COVID-19. Severe forms of COVID-19 include acute respiratory distress syndrome (ARDS) associated with cytokine release syndrome that can culminate in multiorgan failure and death. Among the proinflammatory factors associated with severe COVID-19 are the chemokines CCL2, CCL3, CXCL8 and CXCL10. Infection of susceptible mice with murine coronaviruses, such as mouse hepatitis virus (MHV), elicits a similar chemokine response profile as observed in COVID-19 patients and these in vivo models have been informative and show that targeting chemokines reduces the severity of inflammation in target organs.
Areas covered: PubMed was used using keywords: Chemokines and coronaviruses; Chemokines and mouse hepatitis virus; Chemokines and COVID-19. Clinicaltrials.gov was used using keywords: COVID-19 and chemokines; COVID-19 and cytokines; COVID-19 and neutrophil.
Expert opinion: Chemokines and chemokine receptors are clinically relevant therapeutic targets for reducing coronavirus-induced inflammation.
Keywords: Coronavirus; chemokine receptors; chemokines; clinical targets; inflammation.
. 2021 Dec 29.
doi: 10.1080/1744666X.2022.2017282. Online ahead of print.
Evaluating the role of chemokines and chemokine receptors involved in coronavirus infection
Gema Olivarria[SUP] 1 [/SUP], Thomas E Lane[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 34964406
- DOI: 10.1080/1744666X.2022.2017282
Abstract
Introduction: Coronaviruses are a large family of positive-stranded non-segmented RNA viruses with genomes of 26-32 kilobases in length. Human coronaviruses are commonly associated with mild respiratory illness; however, the past three decades have seen the emergence of severe acute respiratory coronavirus (SARS-CoV), middle eastern respiratory coronavirus (MERS-CoV), and SARS-CoV-2 which is the etiologic agent for COVID-19. Severe forms of COVID-19 include acute respiratory distress syndrome (ARDS) associated with cytokine release syndrome that can culminate in multiorgan failure and death. Among the proinflammatory factors associated with severe COVID-19 are the chemokines CCL2, CCL3, CXCL8 and CXCL10. Infection of susceptible mice with murine coronaviruses, such as mouse hepatitis virus (MHV), elicits a similar chemokine response profile as observed in COVID-19 patients and these in vivo models have been informative and show that targeting chemokines reduces the severity of inflammation in target organs.
Areas covered: PubMed was used using keywords: Chemokines and coronaviruses; Chemokines and mouse hepatitis virus; Chemokines and COVID-19. Clinicaltrials.gov was used using keywords: COVID-19 and chemokines; COVID-19 and cytokines; COVID-19 and neutrophil.
Expert opinion: Chemokines and chemokine receptors are clinically relevant therapeutic targets for reducing coronavirus-induced inflammation.
Keywords: Coronavirus; chemokine receptors; chemokines; clinical targets; inflammation.